The tricky business is defining effectiveness (and the target population). This drug was not effective at the specified clinical end-point for one set of patients. But it did show promise for other end-points (production of a normal dystrophin transcript).

For complex diseases with a range of severities, failing the specified clinical endpoint is not the same as selling dyed water.